Compare FATE & GPMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FATE | GPMT |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.5M | 131.8M |
| IPO Year | 2013 | 2017 |
| Metric | FATE | GPMT |
|---|---|---|
| Price | $1.11 | $2.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $3.92 | $3.13 |
| AVG Volume (30 Days) | ★ 1.4M | 171.0K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 7.17% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,137,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $1.61 |
| 52 Week High | $2.93 | $3.49 |
| Indicator | FATE | GPMT |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 51.23 |
| Support Level | $0.99 | $2.72 |
| Resistance Level | $1.16 | $2.81 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 73.17 | 70.00 |
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the property.